Scienza e Tecnologia
Regenics Appoints Brynjólfur Gísli Eyjólfsson as Chair of the Board
commented:
"It is an honor to take on the role of Chair at Regenics. We believe the company's marine-based platform and its lead product Collex® have strong clinical and commercial potential. Nordic Blue and Haf Investments are committed to supporting the company as it moves into clinical development."
The company would like to take the opportunity to thank outgoing board chair for all his efforts in successfully leading the company the past four years.
Regenics is a Norwegian biotech company developing next-generation wound care solutions based on marine bioactives sourced from the Norwegian coast. Its proprietary HTX™ technology, derived from salmon roe, is the basis of Collex® - an advanced hydrogel dressing currently completing preclinical studies for partial-thickness burns and chronic wounds.
Mr. Eyjólfsson has over 25 years of experience in seafood operations and financial management. He has previously held leadership positions at PwC and Brim and currently manages the Haf Investments fund with a focus on blue economy investments in the Arctic region.
Haf Investments (IS Haf Fjárfestingar slhf.) is a private equity fund managed by Iceland Funds with a focus on sustainable investments in seafood, marine biotechnology, and the blue economy. The fund is the largest investor in Nordic Blue hf., an Icelandic investment company with significant holdings in Regenics.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/regenics-as/r/regenics-appoints-brynjolfur-gisli-eyjolfsson-as-chair-of-the-board,c4167422
View original content:https://www.prnewswire.co.uk/news-releases/regenics-appoints-brynjolfur-gisli-eyjolfsson-as-chair-of-the-board-302493194.html